Joe...The 10QSB states that the reason for the delay in providing the
results of the Barbados Clinical Trials is that <<as of June 30, 1997 the
results are not yet completed>>. Even though this is obviously true it leads to
speculation as to why results are not completed. Could it be because
there is not enough funding, or because Dr. Hirschman is too busy with
administrative duties to review the report or even because results are not
acceptable for some reason or another? I DOUBT IT!
I interpreted the delay in reporting results to mean that the Barbados
Trials have been deliberately extended, by Dr. Hirschman, in order to
develop results that can combat, to some degree, question regarding the
long term effectiveness of Reticulose against AIDS.
If things are going so well, where the patients are still alive and blood
sample data are still being obtained from them, then lets applied what I
call "reverse logic". That is, "the longer it takes for the Barbados Report
to come out the better it is for Reticulose, ADVR and Dr.Hirschman and the
shareholders." In the short run, the longer it takes for the Barbados Report
to come out, the more frustrating it is to the shareholders. However, in
the long run, it may be extremely beneficial in overcoming further delay
for FDA approval where the FDA might require a new clinical trial if Dr.
Hirschman could not provide information regarding long term results. In
other words, by extending the Barbados Study, Dr. Hirschman is getting
ahead of the power curve.
If I am right that there has been a deliberate action on the part of ADVR to
extend the Barbados Clinical Trials for long term data, then it is certainly
wonderful to surmise that the participating patients are still alive, after
one year, and that data can still be obtained from this Clinical Trial.
The Kingfisher |
